Please find enclosed herewith transcript of Con Call arranged on 20.05.2026.
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dishman Carbogen Amcis reported strong Q4 FY26 results with revenue of INR 851 crores (up 19% YoY) and full-year revenue of INR 2,932 crores (up 8%). EBITDA for FY26 stood at INR 565 crores with a margin of 19.3%, improving 200 basis points from 17.3% in FY25. The company aims to reach 25% EBITDA margin by FY28 with 22-23% margin expected in FY27. Key highlights include a tech transfer of a CHF 20-25 million molecule from Switzerland to India, ADC business contributing 25% of CDMO revenues, and a Board-approved plan for promoter-funded ECB to refinance INR 800 crores of high-cost India debt (currently at 10.5-11%) with cheaper foreign currency debt, expected to reduce quarterly interest costs to INR 30-35 crores from Q2/Q3 FY27.
The margin improvement trajectory and debt refinancing plan are positive for shareholders as they signal better profitability and lower interest burden ahead. The ADC and tech transfer opportunities provide clear revenue growth visibility for FY28.